Loading...
•
Sep 30, 2020
Incyte Q3 2020 Earnings Report
Incyte reported a robust third quarter, marked by strong performance across Jakafi indications, successful U.S. launches of Monjuvi and Pemazyre, and increased royalty revenues from partnered medicines.
Key Takeaways
Incyte reported strong Q3 2020 financial results, driven by Jakafi sales, successful launches of Monjuvi and Pemazyre, and increasing royalty revenues. The company is also advancing its dermatology franchise and key clinical programs.
Reported strong quarter with continued strength across all Jakafi indications.
Experienced good momentum behind the U.S. launches of both Monjuvi and Pemazyre.
Observed increasing royalty contributions from partnered medicines globally.
Established Incyte Dermatology as a new franchise for Incyte in the U.S.
Incyte
Incyte
Incyte Revenue by Segment
Incyte Revenue by Geographic Location
Revenue by Segment
Jakafi Revenue
CapyFin.comRevenue by Geographic Location
Jakavi Royalty Revenue
CapyFin.comOlumiant Royalty Revenue
CapyFin.com Forward Guidance
Incyte has tightened its full year 2020 guidance for Jakafi net product revenues.